WEBINAR
Patient Recruitment & Retention – Challenges & Best Practices
Speaker: Gretchen E. Goller
Patient optimization, recruitment and retention, a key determinant of the success of a clinical trial, has always been a challenge. It is becoming more challenging with the increased complexity of clinical trial design, stringent eligibility criteria and the trend toward more targeted patient population. Considering importance of patient recruitment & retention in clinical trials to achieve the business objective, MakroCare SMO is bringing together the experts from Industry and Site to share their views on barriers/challenges in patient recruitment & retention, various strategies, best practices and new methods to overcome these challenges and reach the targeted patient populations.
Key Topics:
Challenges in patient recruitment & retention
Changing landscape of investigational sites
Strategies, best practices & new methods to adapt
Mining patient records for recruitment
Maximizing partnership between sponsor/CRO and sites
Webinar: From your own Desk (Internet connection and head set / speakers)
Cost: None
Who should participate? Clinical Operational professionals in Medical / Healthcare / Pharmaceutical / Biotech /Medical device industries.
Email: Send your information for registration to [email protected]
Limited Participants: Maximum 50 only
About MakroCare:
MakroCare is an international drug development partner that is dedicated to efficient, high-level performance in combination with unparalleled client satisfaction. MakroCare has 4 subsidiaries/divisions – CRO, Consulting, SMO and Informatics. MakroCare has teams positioned worldwide in these divisions supporting start from clinical to commercializing, regulatory affairs, risk management, trial management (clinical, late phase), monitoring, biometrics (CDM, EDC, Biostatistics, SAS programming, medical writing), QA audits, drug safety / Pharmacovigilance, site management, patient recruitment, informatics (EDC, CTMS, IVRS), contact center and various aspects of drug development.